CLARET ASSET MANAGEMENT Corp lessened its stake in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 6.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 86,474 shares of the company’s stock after selling 6,041 shares during the quarter. Taro Pharmaceutical Industries comprises 1.3% of CLARET ASSET MANAGEMENT Corp’s portfolio, making the stock its 21st largest holding. CLARET ASSET MANAGEMENT Corp’s holdings in Taro Pharmaceutical Industries were worth $6,524,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently bought and sold shares of the company. Commonwealth Bank of Australia grew its holdings in Taro Pharmaceutical Industries by 62.5% during the 2nd quarter. Commonwealth Bank of Australia now owns 1,300 shares of the company’s stock valued at $111,000 after buying an additional 500 shares in the last quarter. Jane Street Group LLC purchased a new position in Taro Pharmaceutical Industries during the 2nd quarter valued at about $290,000. Tower Research Capital LLC TRC grew its holdings in Taro Pharmaceutical Industries by 500.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,810 shares of the company’s stock valued at $325,000 after buying an additional 3,176 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Taro Pharmaceutical Industries during the second quarter worth about $337,000. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of Taro Pharmaceutical Industries by 61.6% during the second quarter. Cubist Systematic Strategies LLC now owns 4,083 shares of the company’s stock worth $349,000 after purchasing an additional 1,556 shares in the last quarter. 10.16% of the stock is owned by institutional investors and hedge funds.
TARO has been the subject of several recent analyst reports. ValuEngine raised Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. HC Wainwright cut their price objective on Taro Pharmaceutical Industries from $115.00 to $105.00 and set a “buy” rating for the company in a report on Monday, August 12th. Finally, Zacks Investment Research raised Taro Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 13th.
Shares of NYSE TARO traded up $1.40 during midday trading on Friday, hitting $75.85. 2,084 shares of the company’s stock were exchanged, compared to its average volume of 56,499. Taro Pharmaceutical Industries Ltd. has a 12-month low of $72.97 and a 12-month high of $109.42. The company has a market cap of $2.86 billion, a price-to-earnings ratio of 10.52 and a beta of 0.42. The business’s fifty day moving average price is $78.37 and its two-hundred day moving average price is $89.93.
Taro Pharmaceutical Industries (NYSE:TARO) last issued its quarterly earnings data on Thursday, August 8th. The company reported $1.72 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.96 by ($0.24). Taro Pharmaceutical Industries had a return on equity of 13.90% and a net margin of 41.49%. The business had revenue of $161.30 million for the quarter, compared to analysts’ expectations of $169.80 million. On average, equities research analysts forecast that Taro Pharmaceutical Industries Ltd. will post 7.33 earnings per share for the current year.
Taro Pharmaceutical Industries Profile
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Recommended Story: Risk Tolerance and Your Investment Decisions
Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.